CD86 and neoplasm: demonstrated an association between dendritic cell (DC) activation markers (CD86, HLA-DR, OX40L) within the SLN tumor and overall survival (OS), with lowest expression in patients with OS < 1 year and highest in those with OS > 8 years (39).